drugset / Trial / NCT01599325

Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome

NCT01599325 ↗

Phase 2 Completed 72 enrolled Celgene Corporation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine whether azacitidine is safe and effective in the treatment of Chinese patients with higher risk Myelodysplastic Syndromes (MDS).

Timeline

Start
2012-07-24
Primary completion
2015-01-29
Completion
2018-03-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 75 mg/m2 Subcutaneous